REDWOOD CITY, Calif. - Jasper Therapeutics, Inc. (NASDAQ:JSPR), a biotechnology company, has announced the presentation of encouraging preclinical study results for their novel antibody therapy, briquilimab, at the American Academy of Allergy, Asthma & Immunology Annual Meeting. The conference is taking place from today until February 26 in Washington, D.C.
The presented studies utilized Jasper's proprietary c-Kit Mouse™, designed to test briquilimab across various disease models. The results from two poster presentations showed that a single dose of briquilimab protected against anaphylaxis in mice, as indicated by significantly higher core body temperatures compared to untreated animals. These studies focused on Mrgprb2-mediated drug-induced anaphylaxis (DIA) and passive systemic anaphylaxis (PSA).
Furthermore, an oral presentation highlighted a study on allergic asthma, demonstrating that one dose of briquilimab significantly reduced lung mast cells and eosinophils in bronchoalveolar lavage, suggesting potential in preventing allergic asthma via mast cell depletion.
Wendy Pang, M.D., Ph.D., Senior Vice President of Research and Translational Medicine at Jasper, expressed optimism about the preclinical results indicating that briquilimab could mitigate severe allergic reactions and anaphylaxis. Edwin Tucker, M.D., Chief Medical Officer, noted the broad potential of briquilimab in various mast cell-driven diseases and its critical role in informing their clinical development programs.
Briquilimab is a targeted monoclonal antibody that inhibits the c-Kit receptor, leading to mast cell depletion. It is currently in clinical studies for conditions such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), as well as for lower to intermediate risk myelodysplastic syndromes (MDS) and as a conditioning agent for stem cell transplants in rare diseases.
The company has conducted clinical trials involving over 145 participants, exploring briquilimab's efficacy and safety profile as a conditioning agent in various diseases, including severe combined immunodeficiency (SCID), acute myeloid leukemia (AML), MDS, Fanconi Anemia (FA), and sickle cell disease (SCD).
This news is based on a press release statement from Jasper Therapeutics and has not been independently verified. Jasper Therapeutics has made forward-looking statements regarding the potential of briquilimab, which are subject to risks and uncertainties. Investors should note that actual results may differ from these projections.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.